Summer Symposium 2014

RNA Biology, Cancer and Therapeutic Implications

The 13th Annual Koch Institute Summer Symposium, “RNA Biology, Cancer and Therapeutic Implications,” took place on Friday, June 13, 2014 at Kresge Auditorium on the MIT campus in Cambridge, Massachusetts. The symposium focused on the molecular and cellular mechanisms underlying RNA-based gene regulation in cancer. More than 1,000 cancer researchers, RNA biologists, and clinical oncologists convened to hear updates on the latest breakthroughs in the creation of RNA-based gene-editing tools and the development and intracellular delivery of RNA-cancer medicines.

Speakers and Presentations

Introduction

Tyler Jacks, PhD
Director, Koch Institute for Integrative Cancer Research
David H. Koch Professor of Biology, Massachusetts Institute of Technology
Investigator, Howard Hughes Medical Institute

View video

Why RNA Biology

Phillip Sharp, PhD
Institute Professor, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

View video

MicroRNAs, Poly(A) Tails and Post-transcriptional Gene Regulation

David Bartel, PhD
Member, Whitehead Institute
Professor of Biology, Massachusetts Institute of Technology

Investigator, Howard Hughes Medical Institute

View video

Novel microRNA Functions in Mammalian Physiology and Cancer

Joshua Mendell, MD, PhD
Professor of Molecular Biology, UT Southwestern Medical Center

View video

Targeting siRNA Delivery to Tumors

Sangeeta Bhatia, MD, PhD
John J. and Dorothy Wilson Professor of Health Sciences and Technology & Electrical Engineering
and Computer Science, Massachusetts Institute of Technology
Director, Laboratory for Multiscale Regenerative Technologies, Koch Institute for Integrative Cancer Research
Investigator, Howard Hughes Medical Institute

View video

Intracellular RNA Delivery

Daniel Anderson, PhD
Samuel A. Goldblith Professor of Applied Biology and Associate Professor, Chemical Engineering and Institute for Medical Engineering and Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Progress in Advancement of RNAi Therapeutics

John Maraganore, PhD
CEO and Director, Alnylam Pharmaceuticals

View video


The Human RNase H1 Degradasome, Biological Roles and Roles in Antisense Pharmacology

Stan Crooke, MD, PhD
Chairman of the Board and Chief Executive Officer, Isis Pharmaceuticals, Inc.

View video

The Biology of CRISPRs: From Genome Defense to Genetic Engineering

Jennifer Doudna, PhD
Professor of Molecular and Cell Biology and Chemistry, University of California, Berkeley
Investigator, Howard Hughes Medical Institute

View video

Regulatory Interactions Between RNA and Polycomb Repressive Complex 2

Jeannie Lee, MD, PhD
Professor of Genetics (and Pathology), Massachusetts General Hospital
Investigator, Howard Hughes Medical Institute

View video

Long Non-coding RNAs: Molecular Regulators of Cell Fate

Laurie Boyer, PhD
Irwin and Helen Sizer Career Development Associate Professor of Biology, Massachusetts Institute of Technology
Koch Institute for Integrative Cancer Research

View video

Tumor Suppressor and Tumor Maintenance Genes

Scott Lowe, PhD
Associate Director for Basic Cancer Research, Cancer Biology and Genetics Program; Chair, Geoffrey Beene Cancer Research Center, Memorial Sloan-Kettering Cancer Center
Investigator, Howard Hughes Medical Institute

View video

Closing Remarks

Tyler Jacks, PhD 
Director, Koch Institute for Integrative Cancer Research
David H. Koch Professor of Biology, Massachusetts Institute of Technology
Investigator, Howard Hughes Medical Institute

View video

We gratefully acknowledge our

Partners                                  

Biogen Idec Foundation

Affiliates                                    

Isis Pharmaceuticals
Janssen R&D LLC
Moderna Therapeutics
Onkaido Therapeutics
Thermo Fisher Scientific Inc.  

Collaborators                        

Agilent Technologies, Inc.
Alnylam Pharmaceuticals Inc
Biosearch Technologies
Sanofi
Sarepta Therapeutics

Sponsors                      

Aveo Oncology Inc.
Cell Signaling Technology, Inc.
CureVac GmbH
Merrimack Pharmaceuticals, Inc.
Mirrx Therapeutics A/S
New England Biolabs
Novartis
RaNA Therapeutics

Grant Support

This activity is supported by an educational donation provided by Amgen.

Vendors

Beckman Coulter
Biomedical Tech
Cell Signaling Technology
EMD Millipore
Intellicyt
Labcyte
New England Biolabs 
Precision Biosystems
Qiagen
Simport  
Taconic